Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.

Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.

Abstract: The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.

Abstract: The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.

Abstract: The present invention provides a method for treating brain injury or stroke in a subject in need thereof, comprising implanting a microdialysis probe into the injury or insult core of the subject and perfusing the probe with an oncotic agent dissolved in a physiologically acceptable buffer, wherein the microdialysis probe comprises a dialysis membrane with a molecular weight cutoff less than the molecular weight of the oncotic agent.

Abstract: The present invention provides a method of treating neural injury, e.g., spinal cord injury (SCI), or enhancing recovery from the neural injury with silymarin or silybin.

Abstract: Disclosed herein is a controlled release particle comprising a therapeutically effective amount of acid fibroblast growth factor (aFGF), entrapped by a particle composed by a biocompatible anionic biopolymer capable of binding to aFGF, and a cationic polymer. The method for manufacturing the controlled release particle and the method of using the particle for treating nervous injury are also provided.

Abstract: The invention provides a method of functionally connecting a portion of the peripheral nervous system of a vertebrate to a portion of the central or peripheral nervous system of said vertebrate, comprising the steps of bringing the portion of the peripheral nervous system and the portion of the central or peripheral nervous system close to each other, applying to the gap between the two portions a fibrin glue mixture comprising a growth factor, fibrinogen, aprotinin and divalent calcium ions so that the fibrin glue mixture is simultaneously in contact with the two portions, and forming an attachment between the portion of the peripheral nervous system and the portion of the central or peripheral nervous system of said vertebrate.

Abstract: A method for treating neural damage with a composition prepared from roots of bupleurum and scutellaria.

Abstract: An modified peptide of human acidic fibroblast growth factor (aFGF), comprising a native human aFGF shortened by a deletion of a deletion of 20 amino acids from N-terminal of the native human aFGF, and an addition of Alanine (Ala) before the shortened native aFGF is provided.

Abstract: The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.

Abstract: The present invention provides a method of treating neural injury, e.g., spinal cord injury (SCI), or enhancing recovery from the neural injury with silymarin or silybin.

Abstract: A method for treating neural damage with a composition prepared from roots of bupleurum and scutellaria.

Abstract: A laminin-modified polymeric hollow conduit is provided for promoting nerve regeneration across the gap between severed ends of a nerve. The conduit is manufactured by a method involving gas plasma treatment. Utilizing the laminin-modified conduit, functional recovery has been achieved in mammals with a severed spinal cord.

Abstract: An modified peptide of human acidic fibroblast growth factor (aFGF), comprising a native human aFGF shortened by a deletion of a deletion of 20 amino acids from N-terminal of the native human aFGF, and an addition of alanine (Ala) before the shortened native aFGF is provided.

Abstract: A fibrin glue composition is for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. A method is also for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve in a subject which includes topically applying to the damaged nerve the fibrin glue composition of the invention.

Abstract: The present invention provides methods and mixtures for treating unilateral vocal fold paralysis (UVFP) and/or enhancing functional recovery of a damaged recurrent laryngeal nerve (RLN). The method of the present invention comprises applying a fibrin glue mixture to a portion of laryngeal muscle. The fibrin glue mixture comprises a growth factor, fibrinogen, aprotinin and divalent calcium ion.

Abstract: A cell system for treating neurodegenerative disorders in a mammal is provided. The cell system includes a population of neurons differentiated from umbilical mesenchymal stem cells for expressing at least one of tyrosine hydroxylase (TH), dopamine-?-hydroxylase (DBH), glutamate decarboxylase (GAD), aromatic L-amino acid decarboxylase (AADC) and dopaminergic transporter (DAT) in a cell culture. A method for treating neurodegenerative disorders in a mammal is also provided. The method comprises the steps of differentiating umbilical mesenchymal stem cells into a population of neurons that express at least one of TH, DBH, GAD, AADC and DAT in a cell culture, and transplanting the population of neurons into the brain of the mammal.

Abstract: A method for inducing neural differentiation includes treating a bone marrow stem cell with a neurotrophic factor and/or dibutyryl cAMP (dbcAMP), wherein the neurotrophic factor includes or is glial cell line-derived neurotrophic factor (GDNF) or pituitary adenylate cyclase-activating polypeptide (PACAP).

Abstract: A method for promoting axon re-growth and behavior recovery in a subject suffering from a nerve injury is described. The method includes administering a pharmaceutical composition comprising a safe and effective amount of a chondroitinase ABC (CHABC) to an injury site of the nerve injury in the subject.